Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- CARDSIndependent statistical analysis of Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04427280).
- CARESIndependent statistical analysis of Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05714644).
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CARMENAAn independent statistical analysis of the CARMENA phase 3 trial evaluating nephrectomy and sunitinib alone in metastatic renal cell carcinoma, including design, endpoints, planned analysis, and statistical interpretation.
- CARTITUDE-1An independent statistical analysis of CARTITUDE-1, evaluating JNJ-68284528, a BCMA-directed CAR-T therapy in participants with relapsed or refractory multiple myeloma.
- Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02717507).
- CASEIIIndependent statistical analysis of Cytosponge Adequacy Study Evaluation II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02395471).
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CATALYSTIndependent statistical analysis of A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CBGJ398XUS04Independent statistical analysis of BGJ398 for Patients With Tumors With FGFR Genetic Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02160041).
- CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: Complete Statistical AnalysisIndependent statistical analysis of CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00540579).
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR: Complete Statistical AnalysisIndependent statistical analysis of CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR: primary endpoint results, effect estimate with confidence interval,…
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery: Complete Statistical AnalysisIndependent statistical analysis of Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC: Complete Statistical AnalysisIndependent statistical analysis of Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04242173).
- Cerebral Blood Flow During Propofol Anaesthesia: Complete Statistical AnalysisIndependent statistical analysis of Cerebral Blood Flow During Propofol Anaesthesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02951273).
- CERPIndependent statistical analysis of RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the…
- Cervical Cancer Prevention for Black Adults: Complete Statistical AnalysisIndependent statistical analysis of Cervical Cancer Prevention for Black Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04927494).
- Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and Lenalidomide in Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Lenalidomide in Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01133665).
- Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA – NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC): primary endpoint results, effect estimate with confidence…
- CHAARTEDIndependent statistical analysis of CHAARTED (NCT00309985), a randomized phase 3 trial of androgen-deprivation therapy with or without docetaxel in metastatic hormone-sensitive prostate cancer.
- CHALLENGEIndependent statistical analysis of Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer: primary endpoint results, effect estimate…
- CHAMPION 1Independent statistical analysis of A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CHAMPION 2Independent statistical analysis of A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- ChangHER-SCIndependent statistical analysis of Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- CheckMate 8HWIndependent statistical analysis of A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC):…
- CheckMate 914Independent statistical analysis of A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney: primary endpoint…
- CheckMate 915Independent statistical analysis of CheckMate 915, a randomized phase 3 trial of nivolumab plus ipilimumab versus nivolumab alone after complete surgical removal of stage IIIb/c/d or stage IV melanoma.
- CheckMate-017Independent statistical analysis of CheckMate-017, the randomized phase 3 trial of nivolumab versus docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancer, including its overall-survival analysis and statistical…
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-568Independent statistical analysis of CheckMate-568 (NCT02659059), a phase 2 trial of nivolumab plus ipilimumab, with chemotherapy in Part 2, as first-line therapy for stage IV non-small cell lung cancer.
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate-9DWIndependent statistical analysis of CheckMate-9DW, a phase 3 randomized trial evaluating nivolumab plus ipilimumab versus sorafenib or lenvatinib in advanced hepatocellular carcinoma.
- CheckMate901A detailed statistical analysis of CheckMate901, a randomized phase 3 trial evaluating nivolumab, ipilimumab, and standard chemotherapy in untreated inoperable or metastatic urothelial cancer.
- Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease: Complete Statistical AnalysisIndependent statistical analysis of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: Complete Statistical AnalysisIndependent statistical analysis of Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Chemoprevention of Gastric Carcinogenesis: Complete Statistical AnalysisIndependent statistical analysis of Chemoprevention of Gastric Carcinogenesis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02794428).